2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early-stage Hodgkin lymphoma; first-line rituximab maintenance therapy improved outcome in follicular lymphoma; and selected patients with diffuse large-cell lymphoma benefited from the addition of bortezomib.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kikushige, Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246–259 (2011).
Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011).
Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1109016.
Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42–51 (2011).
Bachy, E. et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 28, 822–829 (2010).
Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N. Engl. J. Med. 363, 640–652 (2010).
Borchmann, P. et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol. 29, 4234–4242 (2011).
Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203–212 (2011).
Ruan, J. et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 690–697 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Hallek acts as a consultant for and has received honoraria and research support from Celgene, Mundipharma and Roche. P. Cramer declares no competing interests.
Rights and permissions
About this article
Cite this article
Cramer, P., Hallek, M. New therapeutic targets and treatment strategies. Nat Rev Clin Oncol 9, 72–74 (2012). https://doi.org/10.1038/nrclinonc.2011.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.212